CD58 and hematopoietic and lymphoid cell neoplasm: In summary, CD58 expression in hematological tumors is frequently related to treatment response and longer survival, while CD58 loss contributes to immune evasion, facilitates the emergence of resistance to immunotherapies like CAR-T cell therapy, and indicates a poorer prognosis.